Real-world Evidence Robert Winn, Rebecca Miksad, Dana Rollison: We must use real-world data and lessons from COVID to improve care, equity in communities we serve May 13, 2022Vol.48 No.19By Matthew Bin Han Ong
Cancer History Project Expert panel proposes action plan on health equity May 13, 2022Vol.48 No.19By Alexandria Carolan
Trials & Tribulations Cancer is complex and dynamic—ergo, dose optimization calls for mathematical modeling May 13, 2022Vol.48 No.19By Alexander Anderson, Robert Gillies and Robert Gatenby
Conversation with The Cancer Letter FDA’s Lola Fashoyin-Aje: It’s time to increase racial diversity in trials—here’s a draft guidance for how this can be done May 06, 2022Vol.48 No.18By Matthew Bin Han Ong
Regulatory News Pazdur at FDA-ASCO workshop: Failure to optimize the dose is akin to building a house on quicksand May 06, 2022Vol.48 No.18By Alice Tracey
Capitol Hill Whither ARPA-H? What can Biden’s agency do that cancer centers can’t? May 06, 2022Vol.48 No.18By Paul Goldberg
Guest Editorial Let’s learn from our neighbors from the North as we get the menthol flavor out of cigarettes May 06, 2022Vol.48 No.18By David Balis
Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing April 29, 2022Vol.48 No.17By Alice Tracey
